Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR -Mutated Non-Small Cell Lung Cancer

吉非替尼 埃罗替尼 内科学 肿瘤科 肺癌 临床终点 盐酸厄洛替尼 医学 无进展生存期 随机对照试验 癌症 化疗 表皮生长因子受体
作者
Xiaoshan Wang,Yifeng Bai,Vivek Verma,Ruilian Yu,Wei Tian,Rui Ao,Ying Deng,Xue-Qiang Zhu,Hao Liu,Haixia Pan,Lan Yang,Hansong Bai,Xing Luo,Yan Ping Guo,Mingxiu Zhou,Yuemei Sun,Zi-Can Zhang,Si-Min Li,Xue Yu Cheng,Bangxian Tan
出处
期刊:Journal of the National Cancer Institute [Oxford University Press]
卷期号:115 (6): 742-748 被引量:277
标识
DOI:10.1093/jnci/djac015
摘要

BACKGROUND: Adding radiotherapy (RT) to systemic therapy improves progression-free survival (PFS) and overall survival (OS) in oligometastatic non-small cell lung cancer (NSCLC). Whether these findings translate to epidermal growth factor receptor (EGFR)-mutated NSCLC remains unknown. The SINDAS trial (NCT02893332) evaluated first-line tyrosine kinase inhibitor (TKI) therapy for EGFR-mutated synchronous oligometastatic NSCLC and randomized to upfront RT vs no RT; we now report the prespecified interim analysis at 68% accrual. METHODS: Inclusion criteria were biopsy-proven EGFR-mutated adenocarcinoma (per amplification refractory mutation system or next generation sequencing), with synchronous (newly diagnosed, treatment naïve) oligometastatic (≤5 metastases; ≤2 lesions in any one organ) NSCLC without brain metastases. All patients received a first-generation TKI (gefitinib, erlotinib, or icotinib), and randomization was between no RT vs RT (25-40 Gy in 5 fractions depending on tumor size and location) to all metastases and the primary tumor/involved regional lymphatics. The primary endpoint (intention to treat) was PFS. Secondary endpoints included OS and toxicities. All statistical tests were 2-sided. RESULTS: A total of 133 patients (n = 65 TKI only, n = 68 TKI with RT) were enrolled (2016-2019). The median follow-up was 23.6 months. The respective median PFS was 12.5 months vs 20.2 months (P < .001), and the median OS was 17.4 months vs 25.5 months (P < .001) for TKI only vs TKI with RT. Treatment yielded no grade 5 events and a 6% rate of symptomatic grade 3-4 pneumonitis in the TKI with RT arm. Based on the efficacy results of this prespecified interim analysis, the ethics committee recommended premature cessation of this trial. CONCLUSIONS: As compared with a first-line TKI alone, addition of upfront local therapy using RT statistically significantly improved PFS and OS for EGFR-mutated NSCLC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
李健的应助被阳光的半雪采纳,获得10
1秒前
风趣忻完成签到,获得积分20
1秒前
obito发布了新的文献求助10
1秒前
orixero的应助被噫吁嚱采纳,获得10
2秒前
2秒前
2秒前
yue完成签到,获得积分10
3秒前
3秒前
4秒前
5秒前
丘比特的应助被最好的采纳,获得10
5秒前
一杯芝士发布了新的文献求助10
6秒前
桐桐的应助被风中的宛白采纳,获得10
6秒前
6秒前
渣渣兔完成签到,获得积分10
6秒前
6秒前
张哈哈完成签到,获得积分10
6秒前
leye发布了新的文献求助10
6秒前
帕克完成签到,获得积分10
7秒前
实验室发布了新的文献求助10
7秒前
ZeKaWa的应助被健壮的大有采纳,获得10
7秒前
无限芸遥发布了新的文献求助10
7秒前
7秒前
帅斌完成签到,获得积分10
8秒前
syyy发布了新的文献求助10
8秒前
余漆完成签到,获得积分10
8秒前
阿斯顿风格完成签到,获得积分10
9秒前
9秒前
Vicktor2021完成签到,获得积分10
10秒前
吗喽发布了新的文献求助10
11秒前
12秒前
12秒前
syyy完成签到,获得积分10
13秒前
13秒前
ssc完成签到,获得积分10
14秒前
mmol发布了新的文献求助10
14秒前
null完成签到,获得积分0
14秒前
风趣忻发布了新的文献求助10
14秒前
赘婿的应助被流苏采纳,获得10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182102
求助须知:如何正确求助?哪些是违规求助? 9571775
关于积分的说明 21819723
捐赠科研通 7778500
什么是DOI,文献DOI怎么找? 3433617
关于科研通互助平台的介绍 2557786
邀请新用户注册赠送积分活动 2479651